Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Yi‐Long Wu, Shun Lü, Ying Cheng, +17

Journal of Thoracic Oncology

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Shun Lü, Jie Wang, Yan Yu, +19

Journal of Thoracic Oncology

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Qing Zhou, Chong‐Rui Xu, Ying Cheng, +17

Cancer Cell

Advanced NsclcNovel TherapyMulticenter Phase 3MedicinePathology +7

Early detection of lung cancer by using an autoantibody panel in Chinese population

Shengxiang Ren, Shucai Zhang, Tao Jiang, +13

OncoImmunology

Epidemiology Of CancerImmunology7-Aabs PanelPathologyOncology +14

Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy

Caicun Zhou, Yina Wang, Jun Zhao, +23

Clinical Cancer Research

Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation

Yuankai Shi, Shucai Zhang, Xingsheng Hu, +16

Journal of Thoracic Oncology

Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

Caicun Zhou, Dingzhi Huang, Yun Fan, +18

Journal of Thoracic Oncology

Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome

Mingguo Huang, Shintaro Narita, Norihiko Tsuchiya, +9

Carcinogenesis

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Shun Lü, Jie Wang, Ying Cheng, +21

Lung Cancer

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study

Xinghao Ai, Yueyin Pan, Jianhua Shi, +34

Journal of Thoracic Oncology